A REVIEW OF BCS CLASS II DRUGS AND STRATEGIES FOR IMPROVEMENT IN SOLUBILITY

Santosh Kumar
Research Scholar
Department of Pharmacy
Sunrise University, Alwar, Rajasthan.
sanbpha2021@gmail.com

Dr. Abhishek Kumar
Research Guide
Department of Pharmacy
Sunrise University, Alwar, Rajasthan.

ABSTRACT

This review article's goal is to provide a concise summary of the research on possible excipient effects on intestinal medication permeability and transit. Despite excipients being used in prescription products for decades, a lot of study has been put into determining how they could affect medication bioavailability. Drug formulation modifications, might raise potential excipient problems. The in vivo requirement, also known as a biowaiver, may be waived for certain oral products as a consequence of regulatory authorities' establishment of in vivo bioequivalence requirements. The biopharmaceutics classification system is used to characterize the drug substance and drug product in vitro as part of the biowaiver acceptance criteria. Regarding BCS-based biowaivers, many regulatory advice papers have been published; as a result, the most recent FDA guideline is more stringent than earlier guidance, particularly with relation to excipient risk. Particularly, sugar alcohols have been mentioned as possible excipients that might affect absorption. Here, the hazards of these biowaivers and excipients are covered.

Keywords- *API, Excipients, Bioavailability, BCS Class drug II.*

INTRODUCTION

Hydrophilic carriers are coupled with the medicinal active substances. Amorphous carriers like polyvinylpyrrolidone, crystalline carriers like sugar, and semicrystalline carriers like polyethylene glycol may all be used to create SD. Similar to how APIs themselves may be crystalline, amorphous, or partly crystalline, hydrophilic carriers can also comprise crystalline and amorphous domains. The findings of the solid-state characterization demonstrate that the features of the drug that was included have a significant impact on the structure of the resulting solid dispersion. Here are a few of these examples:

The discovery of smaller crystals in CIN and the recrystallization of CBZ into a unique polymorphic form, both as a consequence of targeted interactions with the carrier, were also observed. This is due to the fact that spray congealing alters the active pharmaceutical ingredient's solid state in MPs, which in turn alters the drug's solubility in in vitro tests. Important physiochemical characteristics of a drug include solubility, intrinsic dissolving rate, ionization lipophilicity, stability, surface area, crystallinity, polymorphism, salt form, and molecular size. A medicine's "crystallinity" refers to its capacity to crystallize into a variety of forms. The efficiency of oral drug absorption is influenced by a number of physiological factors. Factors include the amount of acid in the stomach, how quickly it empties, how quickly food moves through the small intestine, whether bile salts are present, and how permeable the intestinal and biliary membranes are.

Excipients may have three effects on how well drugs are absorbed:

(1) By affecting the disintegration, stability, or stability of the dose formulation;

(2) By affecting the physiological processes that occur in the gastrointestinal tract; or
(3) By affecting all three.

In vivo bioequivalence testing, or BE tests, are necessary for drug research, post-approval manufacturing adjustments, and the production of generic copies of already available medications. These investigations aim to demonstrate that a drug's bioavailability was not substantially affected by a formulation modification. If a certain IR solid oral dosage formulation satisfies the requirements set out by the Biopharmaceutics Classification System, a regulatory framework developed to offer regulatory relief based on in vitro characterisation of the drug ingredient and drug product, clinical BE studies may be skipped. Without having to pay for costly animal testing or carry out pointless human studies, which are both required if BE testing is waived, it will be less expensive to develop new treatments. These are the two main advantages, in my view. For evaluating the bioequivalence of IR solid oral dosage formulations, in vitro investigations are often preferred over the more popular human pharmacokinetic in vivo research.

Classification of BCS Class Drugs

The study states that in vivo bioequivalence studies may be omitted if suitable in vitro data can be utilized to "justify an assumption of equivalent in vivo performance." One example of "acceptable in vitro data" is dissolution. Based on their ability to dissolve in water and pass through the intestinal tract, medicinal compounds are analyzed using the BCS, a scientific procedure. The BCS divides the chemicals used in the manufacture of medicines into four categories.

The BCS permits the use of a biowaiver as long as the active substances in the test product and the reference product are the same. Substances in BCS Classes I and III are affected by this. Even if the salt content of the test product and reference product differs even if both are classified as BCS Class I, a biowaiver may still be approved. The biowaiver, however, is not applicable if the test product includes an unapproved drug substance or an unapproved drug substance ester, ether, isomer, combination of isomers, complex, or derivative. Pro-drugs that are absorbed in their pro-drug form may be treated with biowaivers depending on BCS.

Comparing EMA, FDA, and WHO Requirements for BCS Biowaivers

Increased global investment in pharmaceutical R&D might make life-saving medications more accessible and cheap to people all around the globe. The consequence is that sometimes both the original pharmaceutical firm and the copycat pharmaceutical company simultaneously apply for clearance of their goods from several regulatory authorities. During the medication clearance process, submitting all necessary documentation at once may save time and effort, but delays might happen if regional requirements and regulatory review results differ across agencies in various jurisdictions. It is more effective to turn in all necessary documentation at once. This push toward worldwide harmonisation has been mostly successful because to regulatory authorities' usage of the Biopharmaceutics Classification System. In vivo bioavailability and/or bioequivalence studies may not be required with the BCS to satisfy regulatory agency standards, making it a useful tool in the creation of both unique pharmaceuticals and

replicable medicines. The objectives of this article are to describe the BCS-based biowaiver approach and its function in drug development, as well as to offer a synopsis of the present status of BCS biowaiver implementation in numerous countries throughout the globe. The biowaiver process, which is based on the BCS, is specifically intended to hasten the approval of novel medications.

Management and Genetic Evaluation

Addiction has been related to dopaminergic pathways in the mesolimbic and mesocortical areas. The amygdala, hippocampus, and nucleus accumbens are just a few of the brain regions that work together in intricate circuits with the mesolimbic and ventral tegmental pathways. The prefrontal cortex is the last stop along the mesocorticolimbic pathway. Rats must learn how to press a lever in order to transport an electric pulse to the pathway, and this requires the activation of dopaminergic neurons. To activate their VTAs, some rats may starve themselves on purpose. Together with other brain regions, the mesocorticolimbic dopamine circuitry plays a role in the rewarding consequences of a stimulus. Both incentives and signals indicating when rewards will be received might cause dopaminergic transmission in this system.

DOSAGE METHOD AND OPIOID ABUSE

The widespread abuse of prescription drugs is a significant public health issue. Teenagers and young adults are the age group most likely to use illicit drugs heavily. Some often prescribed drugs may really be misused, abused, or diverted for evil purposes. Some young individuals use prescription drugs for amusement in order to reduce stress, anxiety, or improve academic achievement. Numerous people may get drugs, including intimate friends and family, medical professionals, drug dealers, and even online. Studies indicate a surge in young people's use of prescription drugs in the UK, despite the fact that this topic is seldom looked at on a national basis.

Higher Drug Consumption During Pandemic

To address this situation, drug users and everyone else must work together. One's character may have a role in their capacity to flourish in solitude. Those who overuse drugs or alcohol could feel quite uncomfortable when under quarantine. Drug users may behave differently if their access to substances and movement are restricted. Apparently, people under quarantine in Italy have been escaping because they are anxious to get drugs.

The strain of quarantine may have made some people's mental health issues worse. Addiction poses a threat to both physical and mental health. Anxiety and stress pose the biggest threats to mental health in the community. The new and tougher laws, however, will have an impact on many people's lives and wellbeing, which is anticipated to lead to an increase in alcohol and drug misuse. It was normal to anticipate depression, self-harm, and suicide ideas or attempts. As a consequence, future addicts will have a harder trouble getting narcotics. Due to the existing circumstances, only specialized websites and individual couriers may be used to undertake illicit drug trafficking online.

CS Class IIa medicines; pKa ≤ 5 (weak acid drugs; ibuprofen and ketoprofen)

A nonsteroidal anti-inflammatory drug of the ibuprofen class, etoprofen has analgesic and antipyretic properties. Here is a monograph on biowaivers. Regarding

its classification under the Biopharmaceutics Classification System, its biopharmaceutical characteristics, and the dangers of forgoing in vivo bioequivalence testing in the approval of new immediate-release solid oral dosage forms containing ketoprofen, this monograph is based on prior research as well as some additional experimental data. Both have been reformed in this. This evaluation does not apply to combination products, only to pharmaceutical preparations in which ketoprofen is the only active pharmaceutical component. The intended purpose and expected audience of this collection of monographs have both been discussed in previous dialogues. 1 These monographs aim to provide "a critical evaluation of these and other countries' regulatory documents," in contrast to what was stated in the previous article, which claimed that they "do not intend to simply apply the World Health Organization, United States Food and Drug Administration,3 and/or European Medicine Agency Guidance."

In Silico Simulations to Predict the Pharmacokinetic Profiles of ETO

After a patient has received ETO products, plasma profiles may be predicted using a two-compartment pharmacokinetic model. With the exception of a few small changes to the PK parameters, the structure of the model is quite similar to that described by Matsui et al. The model shows a main body and a number of appendages. Important parameters, such as distribution/elimination rate constants, were retrieved from IV data in order to precisely replicate the dispersion and elimination of ETO. These results were obtained from IV data after the administration of 25 mg per dose intravenously to six healthy participants and 25 mg per dose intravenously to Researchers were able to ascertain that the Peff values for Caco-2 were 4.75 104 cm/s and 4.07 104 cm/s using the GastroPlusTM software suite. We selected the most conservative estimate that was even slightly attainable when it came to duplicating plasma levels in vivo. Both sets of data were used to compare the mean plasma profiles obtained from in vivo bioequivalence experiments with the simulated profiles.

CONCLUSION

The fact that certain excipients decrease the body's capacity to absorb the medication limits the acceptance of biowaivers based on BCS. Excipients may have an impact on active transport, passive permeability, or small intestine transit for drugs in BCS Class III. The vast majority of excipients now in use shouldn't have any impact on drugs classified as BCS Class I. Data available indicate that common excipients in solid oral IR dosage formulations do not seem to affect drug permeability or transit in vivo. One of the few excipients that may alter intestinal transit has been discovered in preclinical investigations and in vitro at doses high enough to impact absorption. However, the current FDAM regulation places tight restrictions on excipient alterations. In especially for BCS Class III medications, these restrictions call for regulatory relief. By examining the databases of failed BE clinical studies caused by excipient changes, it may be feasible to learn which adjustments to excipients or dosage forms are not allowed.

REFERENCES

[1] Van Duong T., Van den Mooter G. The role of the carrier in the formulation of pharmaceutical solid dispersions. Part I: Crystalline and semi-crystalline carriers. Expert

Opin. Drug Deliv. 2016;13:1583–1594. doi: 10.1080/17425247.2016.1198768

[2] Sugano K. Biopharmaceutics modeling and simulations: theory, practice, methods, and applications. New Jersey: Wiley, 2012.

[3] Flanagan T. Potential for pharmaceutical excipients to impact absorption: a mechanistic review for BCS Class 1 and 3 drugs. Eur J Pharm Biopharm: Official Journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2019;141:130–138. doi: 10.1016/j.ejpb.2019.05.020.

[4] Vaithianathan S, Haidar SH, Zhang X, Jiang W, Avon C, Dowling TC, Shao C, Kane M, Hoag SW, Flasar MH, Ting TY, Polli JE. Effect of common excipients on the oral drug absorption of Biopharmaceutics Classification System class 3 Drugs cimetidine and acyclovir. J Pharm Sci. 2016;105(2):996–1005. doi: 10.1002/jps.24643.

[5] Yadav, A. N., Verma, P., Kumar, R., Kumar, V., & Kumar, K. (2017). Current applications and future prospects of eco-friendly microbes. EU Voice, 3(1), 21- 22.

[6] Awuchi, C. G., Amagwula, I. O., Priya, P., Kumar, R., Yezdani, U., & Khan, M. G. (2020). Aflatoxins in foods and feeds: A review on health implications, detection, and control. Bull. Environ. Pharmacol. Life Sci, 9, 149-155.

[7] Kumar, R., Saha, P., Lokare, P., Datta, K., Selvakumar, P., & Chourasia, A. (2022). A Systemic Review of Ocimum sanctum (Tulsi): Morphological Characteristics, Phytoconstituents and Therapeutic Applications. International Journal for Research in Applied Sciences and Biotechnology, 9(2), 221-226.

[8] Vaithianathan S, Haidar SH, Zhang X, Jiang W, Avon C, Dowling TC, Shao C, Kane M, Hoag SW, Flasar MH, Ting TY, Polli JE. Effect of common excipients on the oral drug absorption of Biopharmaceutics Classification System class 3 Drugs cimetidine and acyclovir. J Pharm Sci. 2016;105(2):996–1005. doi: 10.1002/jps.24643.

[9] European Medicines Agency (EMA). Committee for Medicinal Products for Human Use (CHMP), EMA/CHMP/ICH/493213/2018. ICH M9 guideline on biopharmaceutics classification system-based biowaivers (Step 5). 2020.

[10] Food and Drug Administration (FDA). Guidance for industry: M9 Biopharmaceutics Classification System-Based Biowaivers. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER);May 2021.

[11] Roshan, K. (2020). Priya damwani, Shivam kumar, Adarsh suman, Suthar Usha. An overview on health benefits and risk factor associated with coffee. International Journal Research and Analytical Review, 7(2), 237-249.

[12] Umama, Y., Venkatajah, G., Shourabh, R., Kumar, R., Verma, A., Kumar, A., & Gayoor, M. K. (2019). Topic-The scenario of pharmaceuticals and development of microwave as; sisted extraction technique. World J Pharm Pharm Sci, 8(7), 1260-1271.

[13] Bind, A., Das, S., Singh, V. D., Kumar, R., Chourasia, A., & Saha, P. Natural Bioactives For The Potential Management Of Gastric Ulceration. Turkish Journal of Physiotherapy and Rehabilitation, 32(3).

[14] Cook JA, Davit BM, Polli JE. Impact of Biopharmaceutics Classification System-based biowaivers. Mol Pharm. 2010;7(5):1539–1544. doi: 10.1021/mp1001747.

[15] Polli JE. In vitro studies are sometimes better than conventional human pharmacokinetic in vivo studies in assessing bioequivalence of immediate-release solid oral dosage forms. AAPS J. 2008;10(2):289–299. doi: 10.1208/s12248-008-9027-6.

[16] Shah VP, Amidon GL. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm Res 12, 413–420, 1995— Backstory of BCS. AAPS J. 2014;16(5):894–898. doi: 10.1208/s12248-014-9620-9.

[17] Davit BM, Kanfer I, Tsang YC, Cardot JM. BCS Biowaivers: similarities and differences among EMA, FDA, and WHO requirements. AAPS J. 2016;18(3):612– 618. doi: 10.1208/s12248-016-9877-2.

[18] Metry M, Shu Y, Abrahamsson B, Cristofoletti R, Dressman JB, Groot DW, Parr A, Langguth P, Shah VP, Tajiri T, Mehta MU, Polli JE. Biowaiver monographs for immediate release solid oral dosage forms: metformin hydrochloride. J Pharm Sci. 2021;110(4):1513–1526. doi: 10.1016/j.xphs.2021.01.011.

[19] Sahana, S. (2020). Purabi saha, Roshan kumar, Pradipta das, Indranil Chatterjee, Prasit Roy, Sk Abdur Rahamat. A Review of the 2019

Corona virus (COVID- 19) World Journal of Pharmacy and Pharmaceutical science, 9(9), 2367-2381.

[20] Singh, M. K., Kumar, A., Kumar, R., Kumar, P. S., Selvakumar, P., & Chourasia, A. (2022). Effects of Repeated Deep Frying on Refractive Index and Peroxide Value of Selected Vegetable Oils. International Journal for Research in Applied Sciences and Biotechnology, 9(3), 28-31.

[21] Nyarko, R. O., Prakash, A., Kumar, N., Saha, P., & Kumar, R. (2021). Tuberculosis a globalized disease. Asian Journal of Pharmaceutical Research and Development, 9(1), 198-201.

[22] Saha, P., Kumar, R., Nyarko, R. O., Kahwa, I., & Owusu, P. (2021). HERBAL SECONDARY METABOLITE FOR GASTRO-PROTECTIVE ULCER ACTIVITY WITH API STRUCTURES.

[23] Charoo NA, Abdallah DB, Bakheit AA, Haque KU, Hassan HA, Abrahamsson B, et al. Biowaiver monograph for immediate-release solid oral dosage forms: sitagliptin phosphate monohydrate. J Pharm Sci. 2021(1520-6017 (Electronic)); 10.1016/j.xphs.2021.09.031.

[24] Charoo NA, Abdallah DB, Parveen T, Abrahamsson B, Cristofoletti R, Groot DW, Langguth P, Parr A, Polli JE, Mehta M, Shah VP, Tajiri T, Dressman

J. Biowaiver monograph for immediate-release solid oral dosage forms: moxifloxacin hydrochloride. J Pharm Sci. 2020;109(9):2654–2675.

3088-200140080-00001.

doi: 10.1016/j.xphs.2020.06.007.

[25] García MA, Cristofoletti R, Abrahamsson B, Groot DW, Parr A, Polli JE, et al. Biowaiver monograph for immediate-release solid oral dosage forms: carbamazepine. J Pharm Sci. 2021;110(5):1935–1947. 10.1016/j.xphs.2021.02.019.

[26] Rescigno A. Bioequivalence. Pharm Res. 1992;9(7):925–928. doi: 10.1023/a:1015809201503.

[27] Bois FY, Fau TT, Fau HW, Fau CM, Fau PR, Williams RL. Bioequivalence: performance of several measures of rate of absorption. Pharm Res. 1994;11(7):966–974. doi: 10.1023/a:1018970901116.

[28] hinchilli VM, Elswick RK., Jr The multivariate assessment of bioequivalence. J Biopharm Stat. 1997;7(1):113–123. doi: 10.1080/10543409708835173.

[29] Bois FY, Fau TT, Hauck WW, Chen ML, Patnaik R, Williams RL. Bioequivalence: performance of several measures of extent of absorption. Pharm Res. 1994;11(5):715–722. doi: 10.1023/A:1018932430733.

[30] Chen ML, Lesko L, Williams RL. Measures of exposure versus measures of rate and extent of absorption. Clin Pharmacokinet. 2001;40(8):565–572. doi: 10.2165/0000